

BioAlliance Pharma Publishes its first Shareholder Newsletter

Paris, April 29, 2014 - BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces the publication of its first Shareholder Newsletter⁽¹⁾.

This Newsletter completes BioAlliance Pharma's communication with all of its shareholders, in addition to its website, its press releases and its participation in the financial community events.

This first issue follows the press release of April 16, 2014, announcing the planned merger between BioAlliance Pharma and Topotarget to create a leading orphan oncology company. Judith Greciet, CEO of BioAlliance Pharma, addresses shareholders to present this merger's key points: its expected benefits, major assets to drive growth and value, key transaction details and its consequences.

(1) The Shareholder Newsletter is available on the website at: www.bioalliancepharma.com (News or Investors).

About BioAlliance Pharma

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Orphan Oncology products

Livatag[®] (Doxorubicin Transdrug[™]) (primary liver cancer): Phase III on going

Validive[®] (Clonidine Lauriad[®]) (mucositis): Phase II on going

AMEP[®] (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is

providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2013 Reference Document filed with the AMF on April 7, 2014, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (www.bioalliancepharma.com).

BioAlliance Pharma SA

Judith Greciet, CEO

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

nicolas.fellmann@bioalliancepharma.com

Tel.: +33 1 45 58 76 00

ALIZE RP

Caroline Carmagnol

+33 6 64 18 99 59

bap@alizerp.com